麻豆视频

美国马萨诸塞州州立大学麻豆视频 免疫和微生物学博士，副教授，副主任技师，麻豆视频 博士生导师，麻豆视频 附属鼓楼医院科技处副处长、检验科行政副主任，国家重点研发计划青年项目首席科学家，江苏省杰出青年基金获得者。江苏省第六期“333工程”培养对象。长期从事病毒感染免疫及防治策略研究，解析了慢性病毒感染中体液免疫耗竭的机制，为提升抗病毒免疫提供新策略；建立了基于宿主免疫应答的早期预测预警模型，为精准管理高风险人群提供新技术；研发了强效广谱提升体液免疫的抗体药物，为临床精准免疫治疗提供新方案。以第一/通讯作者在Lancet Infect Dis（IF 71.4）、Clin Microbiol Infect（IF 14.2）、J Hazard Mater （IF 12.2）、EMBO Mol Med（IF 9.0）、elife、 mBio等国际高水平期刊发表50余篇SCI论文。主持国家重点研发计划青年项目1项和国家自然科学基金2项，授权国家发明专利4项，其中一项专利以合同金额800万元成果转化。相关研究成果获省科学进步奖三等奖、医学科技进步奖二等奖华夏医学科技奖二等奖等科技奖励。

1．江苏省医院协会第六届医院图书情报管理专业委员会副主任委员

2．《检验医学与临床》杂志第六届编辑委员会青年编委

3．中国女医师协会第四届公共卫生专业委员会委员

4．江苏省研究型医院学会智慧科研管理工作委员会委员兼学术秘书

5．第三届中西医结合学会检验医学专业委员会常务委员

6．江苏省医师协会检验医师分会第四届委员会委员

7．中华医学会肝病学分会肝病基础医学与实验诊断协作组成员

8．第二届中西医结合学会检验医学专业委员会青年委员

9．中国医学装备协会检验医学分会第二届微生物检验装备学组委员

10．中国医疗保健国际交流促进会分子诊断分会第二届委员

11．中科院一区TOP期刊《Emerging Microbes &Infection》审稿编辑

12．《mlife》青年编委

13．《hlife》青年编委

14．《Interdisciplinary Medicine》青年编委

15．高等学校医学规划新形态教材（医学检验技术系列）《医学检验专业英语》编者

16．医学参考报检验医学专刊第五届编委会编委

1.     Zhang W*, Chen J*, Wang L*, Wu Y, Kong W, Chen Y, Hu Z, Zhang Y, Ding Z, Chen Y†. Astragalus polysaccharide and aluminum adjuvant synergize to amplify immune responses induced by a recombinant COVID-19 vaccine. Hum Vaccin Immunother. 2025 Dec;21(1):2559504.

2.     Mingzhi Gan1†, Weiwei Han†, Chuang Li†, Simin Li, Zhuangzhuang Huang,Lingjie Xu, Xiaoyu Xu, Xiangjun Zhai*, Yuxin Chen* and Jingxin Li*. Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population.Frontiers in Immunology. 2025 Oct 1;16.

3.     Zhao L^*, Li C^*, Wang M^*, Zhou M, Jiang L, Zhang W, Yu J, Wang W, Zhou K, Pan K, Lam H-Y, Hung IF-N, Chan K-H, Liu L, Wang F, Zhao X^†, Chen Y^†. Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0155624.

4.     Zhang W^*, Liu H^*, Zhang D^*, Yi Y, Tao L, Huang S, Zhao X, Shao Q, Li P, Zhang J, Pan Y, Lu W, Zhang H^†, Chen Y^†, Weng D^†. Role of Hepatocyte RIPK1 in Maintain-ing Liver Homeostasis during Metabolic Challenges. eLife .2025 Jan 31, 13:RP96798.

5.     Li C^*, Yu J^*, Issa R^*, Wang L, Ning M, Yin S, Li J, Wu C^†, Chen Y^†. CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution. Emerging Microbes & Infections.2024 November 25:2434567.

6.     Chen Y^*, Wang G^*, Li M^*, Wang J, Gu J, Huang R, Wu C^†, Zhang Q^†, Liu Y^†. Virological and Immunological Characteristics of HBeAg-Positive Chronic Hepatitis B Patients With Low HBsAg Levels. Alimentary pharmacology & therapeutics. 2024 Dec 18.

7.     Tian P^*, Zhao L^*, Zhang G^*, Chen S, Zhang W, Ou M, Sun Y^†, Chen Y^†.A global lipid map of severe fever with thrombocytopenia syndrome virus infection reveals glycerophospholipids as novel prognosis biomarkers. mBio. 2024 November 13,0:e02628-24.

8.     Ji M^*, Hu J^*, Zhang D, Huang B, Xu S, Jiang N, Chen Y^†, Wang Y^†, Wu X^†, Wu Z^†. Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody. EMBO Mol Med. 2024 Mar;16(3):575-595.

9.     Chen Y^*†, Zhao T^*, Chen L^*, Jiang G, Geng Y, Li W, Yin S, Tong X, Tao Y, Ni J, Lu Q, Ning M^†, Wu C^†. SARS-CoV-2 Omicron Infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. mBio.2024 Apr 10;15(4):e0240723.

10.Liu Y^*, Zheng H^*, Zhang W^*, Xu Z, Yu J, Song H^†, Gu C^†, Chen Y^†. Establishment and evaluation of Voting algorithm-based internal quality control (ViQC), a patient-based real-time quality control. Clin Chim Acta. 2024 Jul 15;561:119821.

11.Chen L^*, Ma M^*, Zou M^*, Zhao L, Ou M, Geng Y, Li C, Shen H^†, Chen Y^†. Rapid and portable bunyavirus SFTSV RNA testing utilizing catalytic hairpin assembly coupled with lateral flow immunoassay. Microbiol Spectr. 2023 Sep 8;11(5):e0214423.

12.Wang L^*, Li C^*, Li W^*, Zhao L, Zhao T, Chen L, Fan J, Li J, Wu C^†, Chen Y^†. Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities. Emerg Microbes Infect.2023 Dec;12(2):2225640.

13.Zhang W^*, Jie J^*, Xu Q, Wei R, Liao X, Zhang D, Zhang Y, Zhang J, Su G, Chen Y^†, Weng D^†. Characterizing the obesogenic and fatty liver-inducing effects of Acetyl tributyl citrate (ATBC) plasticizer using both in vivo and in vitro models. J Hazard Mater. 2023 Mar 5;445:130548.

14.Xu J^*†, Kerr L, Jiang Y, Suo W, Zhang L, Lao T, Chen Y^*†, Zhang Y^*†. Rapid Antigen Diagnostics as Frontline Testing in the COVID-19 Pandemic. Small Sci. 2022 Aug;2(8):2200009. (IF=12.7)

15.Chen Y^*, Chen L^*, Yin S^*, Tao Y, Zhu L, Tong X, Mao M, Li M, Wan Y, Ni J, Ji X, Dong X, Li J, Huang R, Shen Y, Shen H^†, Bao C^†, Wu C^†. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerg Microbes Infect 2022 Dec;11(1):1524-1536.

16.Zhang J^*, Chen L^*, Xu Q, Tao Y, Pan J, Guo J, Su J, Xie H^† and Chen Y^†. An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensor. Clin Chem Lab Med, 2022 May 11;60(7):1073-1080. (IF=6.8，中科院2区)

17.Chen Y^*, Shengxia Yin^*, Xin Tong^*, Yue Tao, Jun Ni, Jie Pan, Ming Li, Yawen Wan, Minxin Mao, Yali Xiong, Xiaomin Yan, Yue Yang, Rui Huang, Chao Wu, Han Shen^†. Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine. Clinical Microbiology and Infection. 2022 Mar;28(3):410-418. (IF=14.2，中科院1区)

18.Chen Y^*, Zhu L^*, Huang W^*, Tong X, Wu H, Tao Y, Tong B, Huang H, Chen J, Zhao X, Yang L, Wu C^†. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerging Microbes & Infections. 2021 Dec;10(1):1390-1403. (IF=19.5，中科院1区)

19.Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralizing activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis. 2021 Aug;21(8):1071-1072. （IF=71.4，中科院1区）

20.Chen Y^*, Tong X^*, Li Y, Gu B, Yan J, Liu Y, Huang R^†, Wu C^†. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. Plos Pathogen. 2020 Sep 10; 16(9):e1008796.  (IF=6.8，中科院1区)

21.Chen Y^*, Tong X^*, Wang J, Huang W, Yin S, Huang R, Yang H, Chen Y, Huang A, Liu Y, Chen Y, Yuan L, Yan X, Shen H^†, Wu C. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020 Sep;81(3):420-426.(IF=6.0，中科院1区)

22.Yongchen Z^*, Shen H^*, Wang X, Shi X, Li Y, Yan J, Chen Y^†, Gu B^†. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):833-836.(IF=7.1，中科院1区)

23.Li*, Xu Yao*. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. Journal of Allergy and Clinical Immunology2017 May 4.(IF=13.2, 中科院1区)

24.Chen Y, Michael Vaine, Aaron Wallace, Dong Han, Shengqin Wan, Michael S. Seaman, David Montegiori, Shixia Wang, Shan Lu. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.Journal of Virology. 2013, 87(18):10232.

主持课题

1. 江苏省自然科学基金(杰出青年基金项目），BK20250017，发热伴血小板减少综合征重症预警及免疫精准诊疗策略研究，2025-9至2028-8， 180万，在研，主持

2.国家重点研发计划青年科学家项目，2023YFC2309100，新冠病毒疫苗诱导关键免疫调控网络的精准绘制及干预新策略，2023-12至2026-11，400万，在研，主持

3. 国自然科学基金委员会，重大研究计划培育项目，92269118，刺突蛋白特异Tfh细胞作为新冠保护性免疫评价指标及其调控适应性免疫应答的机制研究， 2023-01至2025-12， 60万，在研，主持

4. 国自然科学基金委员会，青年项目，81600201，线粒体Trx2在血管内皮调控ASK1的分子机制及其作为动脉粥样硬化靶点的研究，2017-01至2019-12，17.5万，结题，主持

1. 陈雨欣（2/11）新冠病毒感染的临床特征与防治策略研究，2023年度江苏省科学技术奖三等奖

2. 陈雨欣 （1/9）新冠病毒感染的临床特征与防治策略研究，2024年江苏医学科技奖二等奖

3. 陈雨欣（3/12）发热伴血小板减少综合征病毒传播和感染重症化机制研究，2023年华夏医学科技奖二等奖

4. 陈雨欣（1/3）抗新冠病毒广谱、长效的保护性免疫评价指标的建立及应用，2023年江苏省卫健委医学引进新技术二等奖

5. 陈雨欣（2/5）新型布尼亚病毒感染的基础及临床研究，2020年江苏医学科技奖二等奖